| Phycocyanin — a water-soluble blue phycobiliprotein/chromoprotein found in cyanobacteria and red algae, best characterized as C-phycocyanin from Arthrospira platensis (Spirulina). It consists of α- and β-protein subunits carrying the linear tetrapyrrole chromophore phycocyanobilin. It is formally a natural-product biliprotein and food-derived bioactive rather than a conventional small-molecule drug. Standard abbreviations are PC and C-PC. Phycocyanin should be added as a separate Nestronics product because it is a chemically and functionally defined major bioactive component of Spirulina, has a substantial independent cancer literature, and is also being investigated as a photosensitizer, sonosensitizer, drug carrier, radiosensitizer, and therapeutic protein. It should not be treated as synonymous with whole Spirulina biomass.
Primary mechanisms (ranked):
- Induction of intrinsic and extrinsic apoptosis, including ↓ Bcl-2, ↑ Bax, mitochondrial membrane depolarization, cytochrome-c release and activation of caspases 3, 8 and 9.
- Suppression of proliferative and survival signaling, particularly COX-2/PGE2, MAPK/ERK, PI3K/Akt/mTOR and context-dependent NF-κB signaling.
- Cell-cycle arrest through modulation of cyclins, CDKs, p21 and p27, with G0/G1, S or G2/M arrest depending on tumor model.
- Induction of autophagic cell death in selected cancers through inhibition of PI3K/Akt/mTOR signaling and interaction between autophagy and apoptosis pathways.
- Inhibition of migration, invasion, angiogenesis and metastatic phenotypes, including effects on MAPK, COX-2/PGE2 and related signaling.
- Redox modulation: C-PC is generally antioxidant in normal biological systems but can produce ↑ ROS, mitochondrial oxidative stress and GSH depletion in some cancer models; strong ROS generation also occurs when C-PC is used as a photo- or sonosensitizer.
- Radiosensitization and chemosensitization reported preclinically, including enhancement of radiation, topotecan, cisplatin and taxane-based approaches.
Bioavailability / PK relevance: Native C-PC is a relatively large protein complex and is unstable to heat, acidic pH and gastrointestinal proteolysis. Oral intact-protein systemic bioavailability is therefore expected to be low, and digestion produces phycocyanin-derived peptides and phycocyanobilin with potentially different pharmacology. Encapsulation, nanoparticles, PEGylation and colon-targeted formulations are being investigated specifically because poor stability and delivery limit translation. Food-grade phycocyanin-rich preparations can nevertheless be consumed orally, and approximately 1 g/day phycocyanin-equivalent exposure was used for two weeks in a small human safety RCT.
In-vitro vs systemic exposure relevance: Many anticancer experiments expose cells directly to approximately tens to hundreds of µg/mL C-PC, with some studies using still higher concentrations. These exposures should not be assumed achievable as intact circulating C-PC after ordinary oral supplementation because gastrointestinal degradation and uncertain systemic absorption substantially separate oral exposure from direct cell-culture exposure. Photodynamic and sonodynamic applications are additionally trigger-dependent and should be evaluated separately from unactivated oral C-PC.
Clinical evidence status: Preclinical for cancer treatment. Evidence includes numerous cancer-cell studies and several animal tumor models, but there is no established anticancer indication or validated therapeutic cancer dose in humans. Human exposure data mainly concern food/supplement safety rather than cancer efficacy. A small randomized safety study found a phycocyanin-rich extract providing approximately 1 g/day phycocyanin for two weeks to be well tolerated, but this does not establish anticancer efficacy. Rare IgE-mediated allergy and anaphylaxis to Spirulina/phycocyanin have been documented. Regulatory acceptance of Spirulina/phycocyanin-rich extracts as food ingredients or color additives should not be interpreted as approval of phycocyanin as a cancer drug.
Phycocyanin Cancer Mechanisms
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
Primary Effect |
Notes / Interpretation |
| 1 |
Mitochondrial apoptosis |
↑ Bax/Bcl-2 ratio; ↓ mitochondrial membrane potential; ↑ cytochrome c; ↑ caspase-9 and caspase-3 |
Generally less cytotoxic in tested normal-cell models |
Apoptotic cell death |
One of the most reproducible anticancer effects across leukemia, breast, cervical, prostate and other models. |
| 2 |
COX-2 and PGE2 |
↓ COX-2; ↓ PGE2 |
↓ inflammatory COX-2 activity (context-dependent) |
↓ proliferation, inflammation and tumor-supportive signaling |
C-PC has been described as a selective COX-2 inhibitor. COX-2 suppression is also implicated in radiosensitization and antimetastatic effects. |
| 3 |
PI3K Akt mTOR and autophagy |
↓ PI3K/Akt/mTOR; ↑ autophagy (model-dependent) |
Context-dependent |
Growth inhibition and autophagic cell death |
Especially well characterized in pancreatic cancer, where autophagy and apoptosis cooperate in C-PC-mediated cytotoxicity. |
| 4 |
MAPK survival signaling |
↓ ERK; ↑ p38/JNK or broader MAPK remodeling (model-dependent) |
Context-dependent |
↓ proliferation; ↑ apoptosis; ↓ migration |
Direction varies by cancer model. Breast and pancreatic cancer studies support substantial MAPK involvement. |
| 5 |
NF-κB survival and inflammatory signaling |
Usually ↓ NF-κB pathway activity; occasionally ↑ NF-κB during autophagy/apoptosis balancing (model-dependent) |
Often ↓ inflammatory NF-κB signaling |
↓ proliferation and survival signaling |
RIPK1/NF-κB and TIRAP/NF-κB suppression has been demonstrated in NSCLC. NF-κB responses are not uniformly unidirectional across tumor systems. |
| 6 |
Cell-cycle control |
↓ Cyclin D1/CDK activity; ↑ p21/p27; ↑ G0/G1, S or G2/M arrest (model-dependent) |
Less pronounced in available comparative models |
↓ proliferation |
The arrest phase varies substantially with cell type and exposure conditions. |
| 7 |
ROS and mitochondrial oxidative stress |
↑ ROS; ↓ GSH; ↓ mitochondrial function in selected models (dose-dependent) |
Often ↓ oxidative stress and radical burden |
Selective redox stress and apoptosis |
Important apparent dichotomy: C-PC is broadly antioxidant yet can become pro-oxidant in some cancer cells. ROS generation becomes much stronger with external photodynamic or sonodynamic activation. |
| 8 |
Migration invasion and angiogenesis |
↓ migration; ↓ invasion; ↓ angiogenic phenotype |
Limited evidence of harmful suppression at comparable exposures |
↓ metastatic potential |
Reported in triple-negative breast cancer, NSCLC and other models; mechanisms overlap MAPK and COX-2/PGE2 signaling. |
| 9 |
Radiosensitization |
↑ radiation response; ↓ clonogenic survival |
Relative sparing reported in tested normal colon cells |
↑ radiation cytotoxicity |
Preclinical colon-cancer work links the effect partly to ↓ COX-2. No established human radiosensitizer role. |
| 10 |
Chemosensitization |
↑ response to topotecan, cisplatin and other agents (model-dependent) |
Potential reduction of required cytotoxic exposure remains unproven clinically |
Enhanced combination therapy |
Combination studies are preclinical. Mechanisms include ↑ ROS, caspase activation and altered drug-resistance pathways. |
| 11 |
Photo and sonodynamic activation |
↑ ROS (requires external trigger); ↓ mitochondrial membrane potential; ↑ apoptosis |
Depends strongly on localization and trigger geometry |
Triggered oxidative cytotoxicity |
C-PC can function as a photosensitizer and sonosensitizer. These applications should be distinguished from unactivated C-PC pharmacology. |
| 12 |
Clinical Translation Constraint |
Direct in-vitro exposure frequently exceeds plausible intact systemic exposure after oral dosing |
Food exposure is generally tolerated, but rare allergy including anaphylaxis is documented |
Limits translation from cell culture to oral cancer therapy |
Poor gastrointestinal stability, proteolysis, formulation dependence, heterogeneous preparations and absence of cancer efficacy trials are major constraints. Nanocarriers and protected delivery formulations may materially change exposure. |
|